3-bromo-4-iodo-isothiazole | 202287-54-5

• 分子结构分类: 有机化合物 - 有机卤素化合物 - 芳基卤化物
• 英文名称: 3-bromo-4-iodo-isothiazole
• 英文别名: 3-Bromo-4-iodo-1,2-thiazole
• CAS: 202287-54-5
• 化学式: C₃HBrINS
• 分子量: 289.922
• InChiKey: FRDAIETTXKDGMN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  7
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  41.1
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-bromo-4-iodo-isothiazole 在 sodium periodate 、 碘 作用下， 以 硫酸 为溶剂， 以61%的产率得到3-bromo-4,5-diiodoisothiazole
  参考文献：
  名称：

  Synthesis of bromine-and iodine-containing perhaloisothiazoles

  摘要：

  A method was developed for the synthesis of bromine- and iodine-containing perhaloisothiazales by bromination and iodination of 3-bromoisothiazole prepared from the available 3-hydroxyisothiazole.

  DOI：

  10.1007/bf02495138
• 作为产物：
  描述：

  3-溴异噻唑 在 硫酸 、 碘 、 sodium periodate 作用下， 反应 16.5h， 以1.46 g的产率得到3-bromo-4-iodo-isothiazole
  参考文献：
  名称：

  [EN] PRODRUGS OF 3-BENZOAMIDO-2-AMINOPROPIONIC ACID DERIVATIVES AS MODULATORS OF THE NMDA RECEPTOR
  [FR] PROMÉDICAMENTS DE DÉRIVÉS D'ACIDE 3-BENZOAMIDO-2-AMINOPROPIONIQUE UTILISÉS EN TANT QUE MODULATEURS DU RÉCEPTEUR NMDA

  摘要：

  本发明涉及NMDA受体调节剂的新型前药。该发明的不同方面涉及包含所述化合物的制药组合物以及使用该化合物治疗神经系统疾病或神经精神疾病，例如抑郁症的用途。

  公开号：

  WO2022129041A1

文献信息

• [EN] PRODRUGS OF 3-BENZOAMIDO-2-AMINOPROPIONIC ACID DERIVATIVES AS MODULATORS OF THE NMDA RECEPTOR<br/>[FR] PROMÉDICAMENTS DE DÉRIVÉS D'ACIDE 3-BENZOAMIDO-2-AMINOPROPIONIQUE UTILISÉS EN TANT QUE MODULATEURS DU RÉCEPTEUR NMDA
  申请人：H LUNDBECK AS

  公开号：WO2022129041A1

  公开（公告）日：2022-06-23

  The present invention is directed to novel prodrugs of modulators of the NMDA receptor. Separate aspects of the inventions are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat neurological disorders or neuropsychiatric disorders such as depression.

  本发明涉及NMDA受体调节剂的新型前药。该发明的不同方面涉及包含所述化合物的制药组合物以及使用该化合物治疗神经系统疾病或神经精神疾病，例如抑郁症的用途。
• Novel Small Molecule Bradykinin B₂ Receptor Antagonists
  作者：Christoph Gibson、Karsten Schnatbaum、Jochen R. Pfeifer、Elsa Locardi、Matthias Paschke、Ulf Reimer、Uwe Richter、Dirk Scharn、Alexander Faussner、Thomas Tradler

  DOI：10.1021/jm9002445

  日期：2009.7.23

  Blockade of the bradykinin B, receptor provides therapeutic benefit in hereditary angioedema (HAE) and potentially in many other diseases. Herein, we describe the development of highly potent B, receptor antagonists with a molecular weight of approximately 500 g/mol. First, known quinoline-based B-2 receptor antagonists were stripped down to their shared core motif 53, which turned out to be the minimum pharmacophore. Targeted modifications of 53 resulted in the highly water-soluble lead compound 8a. Extensive exploration of its structure-activity relationship resulted in a series of highly potent B-2 receptor antagonists, featuring a hydrogen bond accepting functionality, which presumably interacts with the side chain of Asn-107 of the B-2 receptor, Optimization of the microsomal stability and cytochrome P450 inhibition eventually led to the discovery of the highly potent and orally available B-2 receptor antagonist 52e (JSM 10292), which showed the best overall properties.
• Palladium-catalyzed reaction of bromine- and iodine-containing isothiazoles with olefins
  作者：S. G. Zlotin、P. G. Kislitsin、O. A. Luk'yanov

  DOI：10.1007/bf02495666

  日期：1998.3

  3-Bromo-4-alkenylisothiazoles were synthesized by the reaction of 3-bromo-4-iodoisothiazole with olefins in the presence of palladium acetate.
• Alkynylisothiazoles
  作者：S. G. Zlotin、P. G. Kislitsin、O. A. Luk'yanov

  DOI：10.1007/bf02495667

  日期：1998.3

  A new synthesis of mono-and dialkynylisothiazoles by cross-coupling of bromine-and iodine-containing isothiazoles with terminal acetylene moieties in the PdCl2(PPh3)(2)-CuI-NEt3 catalytic system has been developed.
• [EN] MODULATORS OF THE NMDA RECEPTOR<br/>[FR] NOUVEAUX MODULATEURS DU RÉCEPTEUR NMDA
  申请人：H LUNDBECK AS

  公开号：WO2022129047A3

  公开（公告）日：2022-07-28